scholarly journals Screening of crucial long non-coding RNAs in oral epithelial dysplasia by serial analysis of gene expression

2015 ◽  
Vol 14 (4) ◽  
pp. 11729-11738 ◽  
Author(s):  
X. Han ◽  
Y.B. Wei ◽  
G. Tian ◽  
Z. Tang ◽  
J.Y. Gao ◽  
...  
Keyword(s):  
Gene Expression ◽  
Epithelial Dysplasia ◽  
Oral Epithelial Dysplasia ◽  
Non Coding Rnas ◽  
Oral Epithelial

scholarly journals Can Immunohistochemistry Serve as an Alternative to Subjective Histopathological Diagnosis of Oral Epithelial Dysplasia?

2013 ◽  
Vol 5 ◽  
pp. BIC.S12951 ◽  
Author(s):  
Ahmad A. AbdulMajeed ◽  
Camile S. Farah
Keyword(s):  
Gene Expression ◽  
Oral Cancer ◽  
Cancer Progression ◽  
Current Knowledge ◽  
Epithelial Dysplasia ◽  
Histopathological Diagnosis ◽  
Hallmarks Of Cancer ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial ◽  
Review Current

Many attempts have been made to identify objective molecular biomarkers to diagnose and prognosticate oral epithelial dysplasia (OED) because histopathological interpretation is subjective and lacks sensitivity. The majority of these efforts describe changes in gene expression at protein level in OED as determined by immunohistochemistry (IHC). However, the literature on these putative markers of oral cancer progression is vast and varied. The main purpose of this article is to review current knowledge on biomarkers of protein expression for OED by IHC approaches. We further discuss these findings in terms of the proposed essential hallmarks of cancer cells to better understand their role in oral oncogenesis.

scholarly journals SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Caroline McCarthy ◽  
Joseph Sacco ◽  
Stefano Fedele ◽  
Michael Ho ◽  
Stephen Porter ◽  
...  
Keyword(s):  
High Risk ◽  
Sodium Valproate ◽  
Study Protocol ◽  
Epigenetic Reprogramming ◽  
Epithelial Dysplasia ◽  
Phase Iii ◽  
Cancer Development ◽  
Randomised Control Trial ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

Abstract Background Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised control trial of VPA as a chemopreventive agent in patients with high-risk oral epithelial dysplasia (OED). The aim of the trial is to gather preliminary evidence of the clinical and biological effects of VPA upon OED and assess the feasibility and acceptability of such a trial, with a view to inform a future definitive phase III study. Methods One hundred and ten patients with high-risk OED will be recruited from up to 10 secondary care sites in the UK and randomised into either VPA or observation only for 4 months. Women of childbearing potential will be excluded due to the teratogenic properties of VPA. Tissue and blood samples will be collected prior to randomisation and on the last day of the intervention/observation-only period (end of 4 months). Clinical measurement and additional safety bloods will be taken at multiple time points during the trial. The primary outcome will be a composite, surrogate endpoint of change in lesion size, change in grade of dysplasia and change in LOH profile at 8 key microsatellite regions. Feasibility outcomes will include recruitment targets, compliance with the study protocol and adverse effects. A qualitative sub-study will explore patient experience and perception of the trial. Discussion The current management options for patients with high-risk OED are limited and mostly include surgical resection and clinical surveillance. However, there remains little evidence whether surgery can effectively lead to a notable reduction in the risk of oral cancer development. Similarly, surveillance is associated with concerns regarding delayed diagnosis of OED progressing to malignancy. The SAVER trial provides an opportunity to investigate the effects of a repurposed, inexpensive and well-tolerated medication as a potential chemopreventive strategy for patients with high-risk OED. The clinical and biological findings of SAVER will inform the appropriateness, design and feasibility of a definitive phase III trial. Trial registration The trial is registered with the European Clinical Trials Database (Eudra-CT 2018-000197-30). (http://www.isrctn.com/ISRCTN12448611). The trial was prospectively registered on 24/04/2018.

Observer agreement in the grading of oral epithelial dysplasia

2003 ◽  
Vol 31 (4) ◽  
pp. 300-305 ◽  
Author(s):  
Brothwell D. J ◽  
Lewis D. W ◽  
Bradley G ◽  
Leong I ◽  
Jordan R. C. K ◽  
...  
Keyword(s):  
Observer Agreement ◽  
Epithelial Dysplasia ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

Evaluation of two classification systems for oral epithelial dysplasia

Oral Diseases ◽  
2021 ◽  
Author(s):  
Bubacar Embaló ◽  
Andressa Fernanda Paza Miguel ◽  
Andrea Cristina Konrath ◽  
Filipe Modolo ◽  
Elena Riet Correa Rivero
Keyword(s):  
Classification Systems ◽  
Epithelial Dysplasia ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

scholarly journals Expression of epithelial glycoprotein (EGP40) in oral epithelial dysplasia and oral squamous cell carcinoma (OSCC)

2020 ◽  
Vol 31 (5) ◽  
pp. 738
Author(s):  
KenniyanKumar Srichinthu ◽  
GS Kumar ◽  
Harikrishnan Prasad ◽  
Muthusamy Rajmohan ◽  
Krishnamurthy Anuthama ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Epithelial Dysplasia ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial
Sign in / Sign up

Export Citation Format

Share Document